Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review
1.11 Retrospectively evaluate for a correlation between tumor response and changes in systolic/diastolic/mean arterial blood pressures in patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies.
1.12 Retrospectively evaluate for differences in tumor response between patients with and without pre-existing hypertension treated with bevacizumab plus or minus chemotherapy with a wide variety of metastatic malignancies.
1.21 Determine if there were differences in bevacizumab induced hypertension rates between different tumor types.
1.22 Evaluate for differences in bevacizumab induced hypertension rates between males and females.
1.23 Examine if there were associations between a particular chemotherapeutic agent(s), that may have had an increased propensity of inducing hypertension when combined with bevacizumab.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review|
|Study Start Date:||February 2006|
|Study Completion Date:||April 2009|
|Primary Completion Date:||April 2009 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00322725
|United States, New Mexico|
|University of New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator:||Fa-Chyi Lee, MD||University of New Mexico|